FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年6月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年6月24日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年6月20日 | 2,500,916,432 | | 0 | | 2,500,916,432 | | 1). 購回股份 (股份購回並註銷) | | -15,775,377 | 0.63 % | RMB | 63.39 | | | 茲提述本公司於 ...

Group 1: Stock Resumption and Suspension - Huasheng Co. plans to acquire 100% of Yixin Technology, leading to stock resumption [1] - Tianyi Ma intends to purchase 100% equity of intelligent self-service equipment company Xingyun Kaiwu, resulting in stock resumption [1] - Guotou Zhonglu is set to acquire controlling interest in Electronic Institute, and will continue to suspend trading [1] - Zhongda An's controlling shareholder is planning to issue shares to specific targets, causing a change in control and continued suspension of trading [1] Group 2: Share Buybacks and Equity Transfers - Inspur Information plans to repurchase shares worth 200 million to 300 million yuan to reduce registered capital [2] - WuXi AppTec has completed a 1 billion yuan share buyback and plans to cancel the shares [2] - Shanghai Mechanical and Electrical's controlling shareholder intends to transfer 5% of shares through an agreement [2] - Cambrian has adjusted the upper limit for share repurchase price to no more than 818.87 yuan per share [2] Group 3: Daily Operations and External Investments - JinkoSolar has achieved a record conversion efficiency of 27.02% for its 182N-type high-efficiency monocrystalline silicon cells [3] - Wanyi Technology has established a joint laboratory for the development of key vacuum measurement equipment for nuclear fusion [3] - Hailianxun's application for a stock swap merger with Hangqilun has been accepted by the Shenzhen Stock Exchange [3] - Baotai has signed a licensing and production agreement with SteinCares for BAT2406 (Dupilumab) injection [3] - Tailinwei's sales of edge AI new products reached a scale of 10 million yuan in the second quarter [3] - Guiguan Electric is investing 9.5 billion yuan in the construction of a photovoltaic project [3] - Songsheng Co. has signed a contract with Chongqing Jingang Transmission for the development of robotic harmonic reducers and intelligent joint technology [3] - Huilv Ecology's silicon optical single-mode products have entered mass production [3] - Hongmian Co. plans to acquire 39.99% equity of Asia Foods for 90.28 million yuan and accept 60% voting rights delegation [3]

Core Viewpoint - WuXi AppTec (02359) announced a share buyback plan to enhance company value and protect shareholder interests, with a total fund of RMB 1 billion allocated for the buyback [1] Group 1: Buyback Plan Details - The second share buyback plan for 2025 was approved on April 8, 2025, allowing the company to repurchase A-shares at a maximum price of RMB 97.24 per share, later adjusted to RMB 95.91 due to profit distribution [1] - The buyback period is set for a maximum of three months from the board's approval date, with all repurchased shares to be canceled and registered capital reduced [1] Group 2: Execution of Buyback - As of June 20, 2025, the company completed the buyback, acquiring 15.7754 million A-shares, representing 0.5462% of the total issued share capital [2] - The highest buyback price was RMB 69.87 per share, the lowest was RMB 52.52, and the average price was RMB 63.39, with a total expenditure of RMB 10 million (excluding transaction fees) [2] - The execution of the buyback plan did not significantly impact the company's operations, finances, or future development, nor did it affect the company's compliance with listing conditions [2]

有關完成2025年第二次回購本公司A股及 註銷本公司A股的公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 茲提述無錫藥明康德新藥開發股份有限公司（「本公司」）於2025年4月8日及2025 年5月14日的公告（「該等公告」），內容有關（其中包括）2025年第二次以集中競 價交易方式回購本公司A股股份方案（「2025年第二次股份回購方案」）及實施 2024年度利潤分配及2025年特別股息分派後調整A股回購價格上限。除非文義 另有所指，否則該等公告已界定的詞語在本公告中具有相同涵義。 為積極維護本公司價值及股東權益，本公司於2025年4月8日召開第三屆董事會 第二十次會議，審議並通過了《關於2025年第二次以集中競價交易方式回購公 司A股股份的議案》，同意使用自有資金和╱或自籌資金以集中競價交易方式 回 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-041 公司已于 2025 年 4 月 9 日在上海证券交易所网站（www.sse.com.cn）及指定 媒体披露《关于回购注销部分股票通知债权人的公告》（公告编号：临 2025-026）， 至今公示期已满 45 天。公示期间未接到债权人申报债权并要求公司清偿债务或者 提供相应担保的情况。 公司曾于 2025 年 3 月 18 日披露《关于 2025 年以集中竞价交易方式回购 A 股 股份的预案》（公告编号：2025-017），且该预案项下的回购方案（以下简称"2025 年第一次回购股份方案"）已于 2025 年 4 月 29 日经公司召开的 2024 年年度股东 大会审议通过。本次回购股份方案不影响 2025 年第一次回购股份方案的独立实施。 二、 回购实施情况 披露了首次回购股份情况，具体内容详见公司于上海证券交易所网站 （www.sse.com.cn）及指定媒体披露的《关于 2025 年第二次以集中竞价交易方式 首次回购公司股份暨股份回购进展公告》（公告编号：临 2025-030）。 易方式回购 A 股股份 15,775,377 股，占 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-041 无锡药明康德新药开发股份有限公司 关于 2025 年第二次股份回购并注销实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2025/4/9 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 4 月 年 | 9 日~2025 | 7 | 月 8 日 | | 预计回购金额 | 10亿元~10亿元 | | | | | 回购价格上限 | 95.91元/股 | | | | | 回购用途 | □减少注册资本 √为维护公司价值及股东权益 | | | | | 实际回购股数 | 15,775,377股 | | | | | 实际回购股数占总股本比例 | 0.5462% | | | | | 实际回购金额 | 1,000,001,057.93元 | | | | | 实际回购价格区间 | 52.52元/股~69.87元/股 | | | | 重要内容提示： 一 ...

金十数据6月23日讯，药明康德公告称，公司已完成2025年第二次股份回购，实际回购股数为15,775,377 股，占总股本的0.5462%，回购金额为1,000,001,057.93元。回购股份将全部用于注销并减少注册资本。 药明康德：已完成10亿元股份回购并计划注销 ...

Group 1 - The Hong Kong innovative drug sector experienced a decline, with several companies showing significant drops in stock prices [1] - Crystal Technology Holdings (02228.HK) fell over 4%, indicating a notable decrease in investor confidence [1] - Ascentage Pharma (06855.HK) also saw a decline of more than 3%, alongside other companies like WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) which followed suit [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical industry, indicating a positive outlook for the sector compared to the overall market performance [23]. Core Insights - The pharmaceutical sector experienced a decline of 4.4% this week, underperforming the Shanghai Composite Index, which fell by 0.5% [2][3]. - The overall valuation of the pharmaceutical sector stands at 28.7 times PE (2025E), ranking it 5th among 31 sub-industries [5][10]. - Recent policies from the National Medical Products Administration (NMPA) aim to support the development of high-end medical devices and accelerate the clinical review process for innovative drugs [12]. - Shengnuo Biopharma forecasts a significant profit increase for H1 2025, with expected net profit ranging from 77.03 million to 94.14 million yuan, marking a year-on-year growth of 253.54% to 332.10% [13]. Market Performance - The pharmaceutical and biotechnology index ranked 29th out of 31 sub-industries this week, with various segments showing declines, including chemical preparations (-5.7%) and medical devices (-3.7%) [2][5]. - The report highlights the strong growth in product revenue and licensing deals in the innovative drug sector over the past three years, with a focus on companies expected to release major products and those involved in the CXO industry [12]. Key Events - The NMPA has approved measures to encourage the innovation of high-end medical devices, including optimizing special approval processes and enhancing regulatory frameworks [12]. - The NMPA has also proposed a 30-day review process for clinical trial applications of innovative drugs, aimed at improving the efficiency of drug development [12].